RING: High Dose Granulocyte Transfusions for the Treatment of Infection in Neutropenia the RING Study (Resolving Infection in Neutropenia with Granulocytes)



Major INCLUSION Eligibility Criteria

- Subjects must have severe neutropenia (ANC < 500/mm3) due to marrow failure caused by underlying disease or therapy.
- Age: >18
- Subjects must have one of the following, as defined in Appendix A:
    - Fungemia
    - Bacteremia
    - Proven or presumptive invasive tissue bacterial infection
    - Proven, probable or presumptive invasive fungal infection

Once determined to be eligible for the study, subjects must be consented (if not previously consented) and randomized within 7 days. The 7-day period will start with the first time the patient meets the eligibility criteria as per the report time of the relevant test results. For presumptive invasive tissue bacterial or fungal infections, the 7-day period will start when the clinical team determines that the subject meets all eligibility criteria. RING study staff must document the date and time this decision is made in the subject‟s study files or medical records. Subjects should receive the first granulocyte transfusion (if on the treatment arm) as soon as possible after randomization; every effort should be made to provide the first transfusion within 48 hours after randomization.

Major EXCLUSION Eligibility Criteria

- Any subject unlikely to survive five days
- Evidence that patient will **NOT** be neutropenic for at least 5 days
- Subjects previously enrolled in this study

For More Information Contact: Erica Barnstable at (608) 263-1974 or pager 6868